The possibility of genetically manipulating the vaccinia virus genome has provided the means to use this virus as a eucaryotic viral vector. Foreign genes can easily be inserted into the vaccinia virus genome by homologous recombination (9) . A number of insertion vectors have been constructed which allow introduction of foreign DNA sequences into the thymidine kinase (tk) region of the viral genome (9) . Selection of recombinant viruses is carried out by isolation of a tk-virus (7, 12) and by the ability of recombinant viruses to express the gene markers P-galactosidase (3) and neomycin (6). Although coexpression of procaryotic markers is a highly efficient approach for the selection of recombinants, their use is not desirable when recombinants are designed for vaccination purposes. Thus far, the only viral genetic marker used for selection of recombinants has been the tk gene (7, 12) . We have previously observed that alterations in the coding sequence of the 14,000-molecularweight (14K) gene are responsible for the small-plaque-size phenotype of variants of vaccinia virus (4, 5) . This observation suggested that the 14K gene could be used as a selectable marker and the flanking sequence could be used as a site of insertion of a foreign gene. To study this possibility, we cloned the neomycin resistance gene (neo) fused to the vaccinia virus promoter pll from the plasmid pVV:NEO (6) into the plasmid pDel 13 ( Fig. 1) . This plasmid contains a 1.2-kilobase-pair fragment of vaccinia virus DNA with the entire coding sequence of the 14K gene (5, 13). A ClaIHindlll fragment of 1.25 kilobase pairs, corresponding to upstream sequences of the 14K gene, was isolated from plasmid pE17 (5, 13). This fragment was cloned between the SalI and HindIII restriction sites of pD13NEO to generate pl4K:NEO (Fig. 1) (Fig. 2B ). These findings showed that 40% of large-plaque-size viruses were generated by homologous recombination with the left flanking sequence of the vector (containing the wild-type 14K gene) while 60% of the recombinants were generated by homologous recombination with the left and right flanking sequences of the pl4K:NEO vector. We conclude that rescue of large-plaque-size vaccinia virus can be used as a visual marker for the selection of viral recombinants.
Genetic stability of large-plaque-size recombinants. We have previously described that besides the small-plaque-size phenotype of variant 48-7, this virus has two other welldefined genetic markers: alterations in the electrophoretic mobility of a 14K envelope protein and an 8-megadalton (MDa) deletion on the left terminus of the viral genome (5, 10, 11). These markers were then used to assess the identity and stability of the large-plaque-size recombinants. As shown in Fig. 3A , immunoblots reacted with monoclonal antibody C3, which is specific for the 14K protein (14, infected with a large-plaque-size recombinant virus containing the neo gene (lane 4). The same pattern was maintained after multiple passages of plaque-purified viral recombinants in cells in culture. Southern blot hybridization analysis established that the large-plaque-size recombinants maintained the 8-MDa deletion at the left end of the viral genome (Fig. 3B) , because hybridization was only observed with the right end (HindIII-B) of vaccinia virus DNA. By DNA hybridization analysis, we also established that the neo gene was inserted into the 14K region of the viral DNA, because digestion with various restriction enzymes gave fragments of expected sizes (Fig. 3C) .
We conclude that the 14K region of vaccinia virus DNA can be used to insert foreign genes and that recombinants derived from variant 48-7 have well-defined and stable genetic markers.
Expression of NEO gene during vaccinia virus infection. It was of importance, for the future use of the 14K gene as an insertion vector, to establish whether the neo gene was expressed in our recombinants. This was documented after examination of single-step growth curves in the presence of the antibiotic G-418 (Fig. 4) . While replication of wild-type virus was markedly inhibited by the antibiotic G-418, as previously described (6), a representative large-plaque-size recombinant, 19, grows as efficiently in the presence of the drug as in its absence. Growth of this recombinant was found to be more efficient than the parental variant 48-7, which normally yields about 106 PFU/ml at 24 h postinfection (4).
The findings shown in Fig. 4 foreign gene insertion. The main advantage of this selection vector is that there is no requirement for metabolic selection (i.e., tk-), there is no need for screening large number of virus plaques by DNA hybridization, and there is no need for the use of foreign gene markers (i.e., p-galactosidase and neo). The 14K gene can also be used in the isolation of recombinants when inserted into a nonessential region (i.e. tK) of the vaccinia virus variant (Gong et al., manuscript in preparation).
The new viral marker is specially designed for the con- struction of highly attenuated recombinants of vaccinia virus. This is because the small-plaque-size variant has a large 8-MDa deletion on the left terminus of the viral genome which markedly decreases virulence in both normal and immunosuppressed animals and has a mutation in the 14K gene (4, 11; manuscript submitted). In vaccinated animals, this deletion mutant elicits a protective immune response against wild-type virus (4) . Moreover, using luciferase as a reported gene, we have found that the tissue tropism of this attenuated variant is the same as that of wild-type virus (16; D. Rodriguez, J. R. Rodriguez, D. Trauber, and M. Esteban, Proc. NatI. Acad. Sci. USA, in press). Since inactivation of the vaccinia virus tk locus results in viruses with reduced virulence (2) , combining the acquisition of an 8-MDa deletion with a tk-phenotype should generate recombinants further decreased in virulence. Thus, it is now possible to generate safe and stable nonvirulent recombinants of vaccinia virus with defined genetic markers for vaccination purposes. This minimizes the chances of producing the kinds of serious complications found in the past with the practice of human vaccination (1 
